ABSTRACT
INTRODUCTION
The Epstein-Barr virus (EBV) infects B cells. In most cases, EBV-positive patients develop a severe form of infectious mononucleosis which typically manifests with fever, tonsillopharyngitis, lymphadenopathy and hepatosplenomegaly. HLH is a rare complication of Epstein-Barr virus (EBV) infection. Deficiencies may be characterized by abnormal activity of lymphocyte function leading to hemophagocytosis and multi-organ failure. Although EBV-associated HLH carries a high mortality rate, quick diagnosis and appropriate treatment can subside the disease. We describe here a patient who developed hepatosplenomegaly and pancytopenia at 2 years of age but achieved automatic recovery. There was no neurological manifestation. At age 10, there was a clinical suspicion of EBV-induced HLH and the patient was given the option of treatment with rituximab.
INTRODUCING THE CASE
A ten-year-old girl diagnosed with pneumonia admitted to the hospital. She received antibiotic treatment due to fever and chills. During the hospitalization period, the patient recovered and developed hemophagocytosis with pancytopenia as well as sores on the lip. The patient underwent BMA and nothing abnormal was found. In spite of treatment, the disease did not subside and she developed fever, abdominal distention and edema in her lower extremities. The patient was then transferred to another hospital and was reexamined once again. Physical examination showed that the patient had decreased deep-tendon reflexes (DTR) and was unable to walk. Brain CT scan revealed that the cerebral ventricles were surrounded by a hypodense area. A chest CT-scan showed the rightsided pleural effusion. A CT scan of the abdomen showed severe hepatosplenomegaly. The patient was positive for EBV antibody. Clindamycin, Hypogammaglobulinemia was not confirmed in the patient because it was not possible to check mutation (the related tests were sent to Germany to examine the type 5 disease). EBV may also be accompanied by hypogammaglobulinemia for a certain period Secondary HLH is associated with immunologic stimulation caused by malignancies and bacterial or congenital infections. The most common causes of secondary HLH are viral infections by EBV, CMV, ProB19 and HIV. EBV-related secondary HLH may occur at any age. A secondary form of HLH may also occur in patients with normal immune systems. However, it may also be seen in patients with immune system defects. 3 , 4 Secondary HLH is a known complication of EBV infection, particularly in patients with x-linked lymphoproliferative disease. 5 The incidence of X-linked lymphoproliferative syndrome is 1 in 1,000,000 male infants. 6, 7 Diagnostic criteria for HLH disease are listed in Table2. Precise mechanism of EBV-induced HLH has recently been found. It means that EBV-infected B 16 as it may be useful for our patient as well. However, it has no significant effect on T cells. The effect of anti-INFa has not been confirmed yet. Finally, treatment-refractory patients, transplant candidates, patients with familial type of HLH, or recurrent disease undergo chemotherapy for 8 weeks. Patients who respond favorably to treatment do not undergo transplantation but those who experience relapse and exhibit neurological symptoms are considered for transplantation.
CONCLUSION
Severe infection of EBV is not associated with lifethreatening condition, but our case study needs urgent treatment. In patients with long-term EBV infection, pancytopenia, coagulopathy and hepatosplenomegaly, the existence of the secondary HLH is in doubt. To confirm the diagnosis, BMA will be performed and the serum ferritin level will be measured as well. For patients with secondary HLH, initial therapy with the HLH-2004 protocol 17 approach is appropriate. Rituximab can be used when HLH is associated with EBV to inhibit the immune response. Thus, the main aim of treatment is to reduce the rate of mortality in patients with HLH.
